Drug search by name

Canagliflozin and Metformin Extended-Release Tablets and Renal dysfunction

Result of checking the interaction of drug Canagliflozin and Metformin Extended-Release Tablets and disease Renal dysfunction for safety when used together.

Check result:

Canagliflozin and Metformin Extended-Release Tablets <> Renal dysfunction

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

The glucose lowering effects of SGLT-2 inhibitors is decreased in patients with worsening renal function. Additionally, SGLT-2 inhibitors increase serum creatinine and decrease eGFR. The elderly and patients with moderate renal impairment are at increased risk of further renal dysfunction. Renal function should be evaluated before treatment initiation and monitored regularly in these patients. The use of SGLT-2 inhibitors in patients with severe renal impairment, end stage renal dysfunction (ESRD), or undergoing dialysis is contraindicated. Based on its mechanism of action, SGLT-2 inhibitors are not expected to be effective in patients with this level of renal dysfunction.

Canagliflozin and Metformin Extended-Release Tablets

Generic Name: canagliflozin / metformin

Brand Name: Invokamet, Invokamet XR

Synonyms: Canagliflozin and metformin, Canagliflozin and Metformin

What is Canagliflozin and Metformin Extended-Release Tablets?